Klin Farmakol Farm. 2013;27(3-4):110-113

Lipid-lowering drugs and their indication in patients with chronic kidney disease

Václav Monhart

Univerzita Karlova v Praze, 1. lékařská fakulta a Ústřední vojenské nemocnice, Interní klinika Synlab Czech s.r.o., Praha

Dyslipidemia in patients with chronic kidney disease contributes to the increase in cardiovascular risk and progression of renal impairment.

The probability of death from cardiovascular complications is higher than that from the consequences of end-stage kidney failure.

The cardioprotective and renoprotective effect of statins and fibrates is not only a lipid-lowering effect, but also an additional effect

unrelated to lipids. Statins reduce cardiovascular risk at all stages of chronic kidney disease, slowing down the decline in renal function,

but their impact on the reduction in albuminuria/proteinuria is not unequivocal. Fibrates, which slow down the progression of diabetic

nephropathy by affecting albuminuria, cannot be administered in severe chronic renal insufficiency or renal failure. Controlled studies

and clinical practice show that monotherapy with statins and fibrates is effective and safe. In the treatment of combined hyperlipidemia,

it is necessary, in addition to selecting a suitable combination of a statin with a fibrate or with a cholesterol absorption inhibitor, to

monitor potential side effects, tolerance and treatment compliance.

Keywords: dyslipidemia, chronic kidney disease, cardiovascular risk, statins, fibrates

Published: December 1, 2013  Show citation